Gyre Therapeutics (GYRE) Long-Term Investments (2010 - 2025)

Gyre Therapeutics (GYRE) has 11 years of Long-Term Investments data on file, last reported at $107.1 million in Q4 2025.

• Long-Term Investments for Q4 2025 came in at $107.1 million, up 66.46% year-over-year; the trailing twelve-month figure through Dec 2025 was $107.1 million (up 66.46% YoY), and the FY2025 annual result was $107.1 million, up 66.46% from the prior year.
• Long-Term Investments rose to $107.1 million in Q4 2025 per GYRE's latest filing, from $64.3 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $107.1 million in Q4 2025 and troughed at $4.7 million in Q4 2023.
• A 4-year average of $54.2 million and a median of $52.5 million in 2022 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2023 and 2024: Long-Term Investments tumbled 88.38% in 2023, then jumped 1261.99% in 2024.
• A 4-year view of Long-Term Investments shows it stood at $40.6 million in 2022, then plunged by 88.38% to $4.7 million in 2023, then jumped by 1261.99% to $64.3 million in 2024, then surged by 66.46% to $107.1 million in 2025.
• Business Quant data shows GYRE's Long-Term Investments at $107.1 million in Q4 2025, $64.3 million in Q4 2024, and $4.7 million in Q4 2023.